HCV and Liver Cancer Hepatitis C virus (HCV) chronically infects liver cells, causing inflammation and oxidative stress over decades. This sustained stress environment ultimately drives the development of hepatocellular carcinoma (HCC) in a significant fraction of chronically infected patients. Understanding what molecular changes make HCV-infected cells malignant is key to new therapies.
p62 as a Stress Accumulator p62/Sqstm1 is a multifunctional scaffold protein that normally directs damaged proteins to the autophagy degradation pathway. Under chronic stress conditions like HCV infection, autophagy is impaired and p62 accumulates in large protein aggregates within liver cells. This accumulation is not neutral - the study shows it actively drives tumor progression.
Phosphorylation Activates p62 The critical event is phosphorylation of p62 at serine 349 (in humans) or serine 351 (in mice). Phospho-p62 gains enhanced affinity for the Keap1 protein - the negative regulator of the Nrf2 transcription factor. By sequestering Keap1, phospho-p62 releases Nrf2 to activate a broad antioxidant and metabolic gene program.
Metabolic Reprogramming for Tumor Growth Once freed, Nrf2 drives a specific metabolic reprogramming that redirects glucose toward the glucuronate pathway and funnels glutamine into glutathione synthesis. This reprogramming provides protection from oxidative stress and supplies the biosynthetic precursors needed for rapid tumor cell proliferation.
Human Tissue Analysis Tumor and adjacent non-tumor liver tissue from HCV-positive HCC patients was immunohistochemically stained for phospho-p62 (Ser349), total p62, and Nrf2 target proteins. The spatial relationship between phospho-p62 accumulation and markers of Nrf2 activity was characterized to establish the clinical relevance of the p62-Nrf2 axis.
Cell Line Experiments HCC cell lines were used to characterize the biochemical mechanism: phospho-p62 constructs were introduced to test their effect on Keap1 binding, Nrf2 nuclear translocation, and target gene activation. Phosphorylation-null mutants (Ser349Ala) served as negative controls confirming that the phosphorylation event is required.
Mouse HCC Model A mouse model of HCC was used to test the in vivo function of p62 phosphorylation. Tumor growth rates and drug sensitivity were compared between animals bearing tumors with wild-type p62 versus phosphorylation-deficient p62 mutants, providing in vivo validation of the cell line observations.
Metabolic Flux Analysis Isotope tracer experiments using 13C-labeled glucose and glutamine were performed in cells with and without activated p62-Nrf2 signaling. This tracked how carbons from each substrate were routed through metabolic pathways, directly demonstrating the diversion of glucose to glucuronate and glutamine to glutathione.
Selective Accumulation in HCC Nodules Immunohistochemical analysis of human HCC specimens showed that phospho-p62 (Ser349) was strongly elevated in tumor regions compared to adjacent non-tumor liver parenchyma. Within the HCV-positive subset, the accumulation was particularly pronounced, consistent with HCV-driven impairment of autophagic clearance allowing phospho-p62 to persist.
Correlation with Nrf2 Activation Regions of high phospho-p62 staining correlated spatially with nuclear Nrf2 localization and elevated expression of canonical Nrf2 target genes (NQO1, GCLM, SLC7A11), demonstrating that phospho-p62 is functionally coupled to Nrf2 activation in the human tumor context.
p62 Competes with Nrf2 for Keap1 Biochemical experiments confirmed that phospho-p62 binds Keap1 with higher affinity than non-phosphorylated p62 and that this binding is mediated by the STGE motif of p62 - the same interface used by Nrf2 to bind Keap1. This competitive displacement mechanism explains how accumulating phospho-p62 activates Nrf2 without any mutation in the Nrf2 or Keap1 genes themselves.
Impaired Autophagy Sustains the Signal HCV-infected cells showed reduced autophagic flux, and p62 clearance was impaired. Restoring autophagy with rapamycin reduced phospho-p62 accumulation and attenuated Nrf2 activation, confirming that autophagy dysfunction is a prerequisite for the pathological amplification of p62-Nrf2 signaling.
Glucose Diverted to Glucuronate Pathway Isotope tracing showed that cells with active p62-Nrf2 signaling routed a significantly greater fraction of glucose carbons through the glucuronate pathway rather than through glycolysis toward the TCA cycle. The glucuronate pathway produces UDP-glucuronate, which is used in drug conjugation reactions - suggesting a role in drug detoxification.
Glutamine Shunted to Glutathione Glutamine carbon tracing showed increased flux into glutamate and then glutathione in p62-Nrf2-active cells. Elevated glutathione levels provide protection against reactive oxygen species, chemotherapy, and immune cell-mediated oxidative killing.
Drug Tolerance Phenotype HCC cells with constitutively active phospho-p62-Nrf2 showed resistance to sorafenib (the standard systemic therapy for advanced HCC) and to oxidative stress-inducing agents. Importantly, Nrf2 inhibition (using ML385 or knockdown) restored sorafenib sensitivity, identifying Nrf2 as a druggable resistance mechanism.
Proliferation Advantage Beyond drug resistance, p62-Nrf2 active cells showed a modest but reproducible proliferation advantage over p62-Nrf2 inactive cells under standard culture conditions. This suggests that the metabolic reprogramming provides not just stress protection but active anabolic support for tumor growth.
Non-Mutational Nrf2 Activation Mutations in KEAP1 or NFE2L2 (the Nrf2 gene) are found in only a minority of HCC cases. This study reveals that HCC - particularly in the HCV context - can achieve equivalent Nrf2 activation through a post-translational mechanism: p62 phosphorylation accumulation. This means that Nrf2 activity cannot be predicted from genetic sequencing alone.
Autophagy-p62-Nrf2 Circuit as a Drug Target The pathway from HCV-induced autophagy impairment, through p62 accumulation and phosphorylation, to Nrf2 activation, represents a therapeutic circuit with multiple intervention points. Autophagy activators, p62 interaction inhibitors, and direct Nrf2 inhibitors each represent potential approaches.
Overcoming Sorafenib Resistance Sorafenib is the first-line systemic therapy for advanced HCC, but response rates are modest and resistance is common. The identification of Nrf2 activation as a sorafenib resistance mechanism - together with the availability of Nrf2 inhibitors - provides a rationale for combination trials of sorafenib plus Nrf2 inhibition in HCV-positive HCC with high phospho-p62 levels.
Biomarker Potential Phospho-p62 (Ser349) immunohistochemistry on diagnostic biopsy tissue could serve as a predictive biomarker for Nrf2-driven sorafenib resistance. Patients with high phospho-p62 staining might be prospectively identified as needing alternative or combination regimens.
Clinical Trials of Nrf2 Inhibition Several Nrf2 inhibitors are in early clinical development. Trials enrolling HCC patients selected by high phospho-p62 or Nrf2 activity biomarkers - combining Nrf2 inhibition with sorafenib - would test whether this mechanism-based combination overcomes resistance.
HCV Eradication and HCC Risk Direct-acting antiviral (DAA) therapy now cures HCV infection in over 95% of treated patients. Whether HCV eradication reduces p62 phosphorylation, restores autophagy flux, and lowers Nrf2 activity in pre-malignant liver cells is an important question for understanding whether DAA therapy reduces not just HCV-related cirrhosis but also HCC risk through this epigenetic mechanism.
p62 Phosphorylation in Other Contexts The p62 phosphorylation mechanism may be relevant beyond HCV-positive HCC. Other conditions causing autophagy impairment - including NAFLD, alcohol-related liver disease, and certain cancer-promoting mutations - could also drive p62 accumulation and Nrf2 activation through the same mechanism. Systematic survey of phospho-p62 across liver disease etiologies is warranted.
Drug Detoxification Implications The finding that Nrf2 activation diverts glucose to the glucuronate pathway - which is used for drug conjugation and excretion - raises the broader question of whether Nrf2-active tumors have systematically altered drug pharmacokinetics. Therapeutic dosing strategies for Nrf2-high tumors may need to be adjusted to account for accelerated drug metabolism.